About Myc-associated zinc finger protein
Myc-associated zinc finger protein (MAZ) is a protein
from Homo sapiens identified by UniProt accession
P56270, 477 residues long.
MolForge cross-references it against 0 known binders and
105 disease associations.
Target properties
| Protein name | Myc-associated zinc finger protein |
| UniProt accession | P56270 |
| Gene | MAZ |
| Organism | Homo sapiens |
| Length | 477 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (105)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.35
- hepatocellular carcinoma · score 0.09
- nonpapillary renal cell carcinoma · score 0.08
- mean platelet volume · score 0.08
- pachyonychia congenita · score 0.07
- neoplasm · score 0.06
- triple-negative breast cancer · score 0.06
- cancer · score 0.05
- Ochoa syndrome · score 0.04
- fetal lower urinary tract obstruction · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P56270-F1 | alphafold | PREDICTED | 58.62 | — |
Amino-acid sequence (477 residues)
MFPVFPCTLL APPFPVLGLD SRGVGGLMNS FPPPQGHAQN PLQVGAELQS RFFASQGCAQ SPFQAAPAPP PTPQAPAAEP LQVDLLPVLA AAQESAAAAA AAAAAAAAVA AAPPAPAAAS TVDTAALKQP PAPPPPPPPV SAPAAEAAPP ASAATIAAAA ATAVVAPTST VAVAPVASAL EKKTKSKGPY ICALCAKEFK NGYNLRRHEA IHTGAKAGRV PSGAMKMPTM VPLSLLSVPQ LSGAGGGGGE AGAGGGAAAV AAGGVVTTTA SGKRIRKNHA CEMCGKAFRD VYHLNRHKLS HSDEKPYQCP VCQQRFKRKD RMSYHVRSHD GAVHKPYNCS HCGKSFSRPD HLNSHVRQVH STERPFKCEK CEAAFATKDR LRAHTVRHEE KVPCHVCGKM LSSAYISDHM KVHSQGPHHV CELCNKGTGE VCPMAAAAAA AAAAAAAAVA APPTAVGSLS GAEGVPVSSQ PLPSQPW
Explore Myc-associated zinc finger protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets